Technical Analysis for COYA - Coya Therapeutics, Inc.

Grade Last Price % Change Price Change
C 7.04 -2.63% -0.19
COYA closed down 2.63 percent on Friday, November 1, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish -2.63%
Crossed Above 50 DMA Bullish -2.63%
Volume Surge Other -2.63%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 19 hours ago
Possible Inside Day about 19 hours ago
60 Minute Opening Range Breakout about 23 hours ago
Up 2% about 23 hours ago
Up 1% about 23 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Coya Therapeutics, Inc. Description

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Immunology Immune System Cell Therapy Metabolic Disease Amyotrophic Lateral Sclerosis T Cells Exosome Frontotemporal Dementia Medicinal Products

Is COYA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.6899
52 Week Low 4.4001
Average Volume 78,536
200-Day Moving Average 7.48
50-Day Moving Average 6.91
20-Day Moving Average 8.01
10-Day Moving Average 8.50
Average True Range 0.91
RSI (14) 45.36
ADX 41.9
+DI 19.71
-DI 20.14
Chandelier Exit (Long, 3 ATRs) 7.51
Chandelier Exit (Short, 3 ATRs) 8.85
Upper Bollinger Bands 10.17
Lower Bollinger Band 5.84
Percent B (%b) 0.28
BandWidth 54.06
MACD Line 0.25
MACD Signal Line 0.51
MACD Histogram -0.2588
Fundamentals Value
Market Cap 101.41 Million
Num Shares 14.4 Million
EPS -1.24
Price-to-Earnings (P/E) Ratio -5.68
Price-to-Sales 0.00
Price-to-Book 9.72
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.61
Resistance 3 (R3) 7.66 7.53 7.51
Resistance 2 (R2) 7.53 7.39 7.50 7.48
Resistance 1 (R1) 7.29 7.30 7.22 7.23 7.45
Pivot Point 7.15 7.15 7.12 7.13 7.15
Support 1 (S1) 6.91 7.01 6.84 6.85 6.63
Support 2 (S2) 6.78 6.92 6.75 6.60
Support 3 (S3) 6.53 6.78 6.57
Support 4 (S4) 6.47